Dosage Forms
Form | Route | Strength |
---|---|---|
Tablet | Oral | 2.,5 mg |
Solution | Oral | |
Liquid | Oral | |
Tablet | Oral | |
Tablet | 2.5 mg/0.025mg | |
Solution | Oral | 0.5 mg/mL |
Tablet | Oral | 25 mcg |
Tablet | Oral | 0.,025 mg |
Prices
Unit description | Cost | Unit |
---|---|---|
Lomotil 2.5-0.025 mg/5ml Liquid 60ml Bottle | 30.86USD | bottle |
Lomotil 2.5-0.025 mg tablet | 1.4USD | tablet |
Lomotil tablet | 1.,12USD | tablet |
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents Not Available
Properties
State Solid Experimental Properties Predicted Properties
Property | Value | Source |
---|---|---|
Water Solubility | 0.00146 mg/mL | ALOGPS |
logP | 5.,74 | ALOGPS |
logP | 5.88 | ChemAxon |
logS | -5.5 | ALOGPS |
pKa (Strongest Basic) | 8.5 | ChemAxon |
Physiological Charge | 1 | ChemAxon |
Hydrogen Acceptor Count | 3 | ChemAxon |
Hydrogen Donor Count | 0 | ChemAxon |
Polar Surface Area | 53.,33 Å2 | ChemAxon |
Rotatable Bond Count | 9 | ChemAxon |
Refractivity | 146.76 m3·mol-1 | ChemAxon |
Polarizability | 51.,1 | ChemAxon |
Rule of Five | No | ChemAxon |
Ghose Filter | No | ChemAxon |
Veber’s Rule | No | ChemAxon |
MDDR-like Rule | Yes | ChemAxon |
Predicted ADMET Features
Property | Value | Probability |
---|---|---|
Human Intestinal Absorption | + | 0.,9903 |
Blood Brain Barrier | + | 0.9592 |
Caco-2 permeable | + | 0.5316 |
P-glycoprotein substrate | Substrate | 0.7094 |
P-glycoprotein inhibitor I | Inhibitor | 0.7045 |
P-glycoprotein inhibitor II | Inhibitor | 0.7845 |
Renal organic cation transporter | Inhibitor | 0.5967 |
CYP450 2C9 substrate | Non-substrate | 0.,8333 |
CYP450 2D6 substrate | Non-substrate | 0.5667 |
CYP450 3A4 substrate | Non-substrate | 0.5988 |
CYP450 1A2 substrate | Non-inhibitor | 0.6827 |
CYP450 2C9 inhibitor | Inhibitor | 0.6701 |
CYP450 2D6 inhibitor | Inhibitor | 0.6461 |
CYP450 2C19 inhibitor | Inhibitor | 0.51 |
CYP450 3A4 inhibitor | Inhibitor | 0.,5797 |
CYP450 inhibitory promiscuity | High CYP Inhibitory Promiscuity | 0.817 |
Ames test | Non AMES toxic | 0.8482 |
Carcinogenicity | Non-carcinogens | 0.839 |
Biodegradation | Not ready biodegradable | 0.9805 |
Rat acute toxicity | 3.3423 LD50, mol/kg | Not applicable |
hERG inhibition (predictor I) | Weak inhibitor | 0.,7969 |
hERG inhibition (predictor II) | Inhibitor | 0.592 |
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties., (23092397)
Spectra
Mass Spec (NIST) Not Available Spectra
Targets
Kind Protein Organism Humans Pharmacological action
Yes
Actions
Agonist
General Function Voltage-gated calcium channel activity Specific Function Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone…, Gen-Namen OPRM1 Uniprot ID P35372 Uniprot Namen Mu-type opioid-rezeptor Molekulargewicht 44778.855 Da
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutische Ziel-Datenbank. Nucleic Acids RES 2002 Jan 1;30(1):412-5.
- E: Loperamid: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8.
- Corazziari E: Rolle der Opioidliganden beim Reizdarmsyndrom. Kann J Gastroenterol. 1999 Mär; 13 Suppl A: 71A-75A.
- Coupar IM: Der peristaltische Reflex im Ratten – Ileum: Hinweise auf funktionelle mu-und Delta-Opiatrezeptoren., J Pharm Pharmacol. 1995 Aug;47(8):643-6.
- De Luca A, Coupar IM: Difenoxin und Loperamid: Studien zu möglichen Mechanismen der intestinalen antisekretorischen Wirkung. Naunyn Schmiedebergs Bogen. 1993 Februar;347(2): 231-7.
Kind Proteinorganismus Mensch Pharmakologische Wirkung
Unbekannt
Aktionen
Agonist
Allgemeine Funktion Opioidrezeptoraktivität Spezifische Funktion G-Protein gekoppelter Rezeptor, der als Rezeptor für endogene Enkephaline und für eine Teilmenge anderer Opioide fungiert., Die Ligandenbindung bewirkt eine Konformationsänderung, die die Signalisierung über Guanin n auslöst… Genname OPRD1 Uniprot ID P41143 Uniprot Name Delta-Typ-Opioidrezeptor Molekulargewicht 40368.235 Da
- Coupar IM: Der peristaltische Reflex im Ratten – Ileum: Nachweis für funktionelle mu-und Delta-Opiatrezeptoren. J Pharm Pharmacol. 1995 Aug;47(8):643-6.,
×
Verbesserung der Patientenergebnisse
Erstellen Sie effektive Tools zur Entscheidungsunterstützung mit dem branchenweit umfassendsten Interaktionsprüfer für Arzneimittel und Arzneimittel.
Mehr erfahren
reated on June 13, 2005 07: 24 / Updated on November 02, 2020 21: 01